Pancreatic cancer study pulled before it started
NCT ID NCT04481204
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test new drug combinations for people with pancreatic cancer that hasn't spread. It planned to compare new treatments against standard chemotherapy in three groups based on how far the cancer had grown. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene test may guide smarter chemo for pancreatic cancer
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Could a Decades-Old parasite drug help fight pancreatic cancer?
- Triple threat against pancreatic cancer: radiation, immunotherapy, and chemotherapy combined
- Experimental combo therapy targets Hard-to-Treat pancreatic cancer
- Promising cocktail may shrink pancreatic tumors before surgery